Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27636618 | 0.80 | HDAC6 (0.39) | KMT2AKDM1A | |
| SCHEMBL1241162 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2CA1CA2ACHECA14 | |
| SCHEMBL22118453 | 0.77 | HTT (0.35) | HTT | |
| SCHEMBL23130631 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2CA1CA2ACHECA14 | |
| SCHEMBL10710117 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2CA1CA2ACHECA14 | |
| SCHEMBL8948329 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2CA1CA2ACHECA14 | |
| SCHEMBL2828705 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2CA1CA2ACHECA14 | |
| SCHEMBL197319 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2CA1CA2ACHECA14 | |
| SCHEMBL15443273 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2CA1CA2CA14ALDH1A1 | |
| SCHEMBL3120791 | 0.74 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA2ACHECA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9427777-B2 | Process for producing charge retention medium | ASAHI GLASS COMPANY, LIMITED (JP) | 2016-08-30 | — | — | US | claimed |
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | claimed |
| JP-62096450-A | — | — | None | — | — | JP | disclosed |
| JP-62252735-A | — | — | None | — | — | JP | disclosed |
| US-12620622-B2 | Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same | DAIKIN INDUSTRIES, LTD. (JP) | 2026-05-05 | — | — | US | disclosed |
| EP-4631934-A1 | FLUORINE-CONTAINING ISOXAZOLE COMPOUND AND METHOD FOR PRODUCING SAME | Unimatec Co., Ltd. (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20250260063-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY | DAIKIN INDUSTRIES, LTD. (JP) | 2025-08-14 | — | — | US | disclosed |
| EP-3780232-B1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE | DAIKIN IND LTD (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20250174720-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12315885-B2 | Electrolytic solution, electrochemical device, lithium-ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2025-05-27 | — | — | US | disclosed |
| EP-4553918-A1 | NEGATIVE ELECTRODE, BATTERY, AND METHOD FOR COVERING BATTERY MATERIAL | DAIKIN INDUSTRIES, LTD. (JP) | 2025-05-14 | — | — | EP | disclosed |
| US-4766238-A | Fluorine-containing compounds, and their preparation and use | DAIKIN INDUSTRIES, LTD. (JP) | 1988-08-23 | — | — | US | disclosed |
| EP-0120368-B1 | ALPHA-FLUOROALKYL CARBOXYLIC ACID ESTERS AND PROCESS FOR PREPARING THE SAME | Daikin Kogyo Co., Ltd. (JP) | 1988-07-20 | — | — | EP | disclosed |
| US-4739123-A | Fluorine-containing compounds, and their preparation and use | DAIKEN INDUSTRIES, LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| JP-S62252735-A | PRODUCTION OF 2-TRIFLUOROMETHYL-3,3,3-TRIFLUOROPROPENE | DAIKIN IND LTD | 1987-11-04 | — | — | JP | disclosed |
| JP-S6296450-A | NOVEL FLUORINE-CONTAINING COMPOUND AND PRODUCTION THEREOF | DAIKIN IND LTD | 1987-05-02 | — | — | JP | disclosed |
| US-4582924-A | REACXTING FLUOROALKYL SILYL KETENE ACETAL WITH KETONE, ACETAL OR ACYL HALIDE | DAIKIN KOGYO CO., LTD. (JP) | 1986-04-15 | — | — | US | disclosed |
| US-4482729-A | Fluoroalkyl silyl ketene acetals and a process for preparing the same | DAIKIN KOGYO CO., LTD. (JP) | 1984-11-13 | — | — | US | disclosed |
| EP-0120368-A2 | Alpha-fluoroalkyl carboxylic acid esters and process for preparing the same | Daikin Kogyo Co., Ltd. (JP) | 1984-10-03 | — | — | EP | disclosed |
| EP-0118889-A2 | Fluoroalkyl silyl ketene acetals and a process for preparing the same | Daikin Kogyo Co., Ltd. (JP) | 1984-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250174720-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | HCN2, HCN1, HCN3 | SMN1; SMN2 1422/4885CA1 207/4885CA2 380/4885 |
| US-12620622-B2 | Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same | ASH2L, OLA1, ODC1 | SMN1; SMN2 1758/4885CA1 167/4885CA2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.